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B-Virus (Cercopithecine herpesvirus 1) 
Infection in Humans and Macaques: 
Potential for Zoonotic Disease
Jennifer L. Huff* and Peter A. Barry*
Nonhuman primates are widely used in biomedical
research because of their genetic, anatomic, and physiologic
similarities to humans. In this setting, human contact directly
with macaques or with their tissues and fluids sometimes
occurs. Cercopithecine herpesvirus 1 (B virus), an alphaherp-
esvirus endemic in Asian macaques, is closely related to her-
pes simplex virus (HSV). Most macaques carry B virus without
overt signs of disease. However, zoonotic infection with B virus
in humans usually results in fatal encephalomyelitis or severe
neurologic impairment. Although the incidence of human infec-
tion with B virus is low, a death rate of >70% before the avail-
ability of antiviral therapy makes this virus a serious zoonotic
threat. Knowledge of the clinical signs and risk factors for
human B-virus disease allows early initiation of antiviral therapy
and prevents severe disease or death.
f the 35 herpesviruses identified in nonhuman primates,
only Cercopithecine herpesvirus 1 (B virus) is known to
be pathogenic for humans. Monkeys of the genus Macaca,
which are widely used as animal models for biomedical
research, naturally carry B virus. Infection in macaques is life-
long, with periodic, usually asymptomatic reactivation.
Approximately 40 cases of zoonotic B-virus infection have
been reported. Considering the number of people in contact
with macaques, this number of cases is quite low. However,
the death rate for B-virus infection before the availability of
antiviral therapy was >70%. Neurologic sequelae are common
in survivors. Treatment with antiviral medication may
decrease the death rate, but rapid diagnosis and initiation of
therapy are essential in controlling the spread of the virus in
the central nervous system and limiting neurologic sequelae.
Discovery of B Virus
The first documented case of human B-virus infection
occurred in 1932 when a researcher (patient W.B.) was bitten
on the hand by an apparently healthy rhesus macaque (Macaca
mulatta) and died of progressive encephalomyelitis 15 days
later. Two research groups obtained samples from patient
W.B.: Gay and Holden and Sabin and Wright (1,2). Both
groups demonstrated a similar disease progression in rabbits
inoculated with nerve tissue from patient W.B. and character-
ized the agent as a herpesvirus. Neither group was able to pro-
duce disease in rhesus macaques, presumably because the
monkeys were already naturally infected with what Sabin’s
group named B virus (after patient W.B.).
The familiar term B virus will be used throughout this arti-
cle. Many other accepted terms for this virus exist, including
Herpesvirus simiae, herpes B, monkey B virus, and herpesvi-
rus B. The International Committee on the Taxonomy of
Viruses uses the name Cercopithecine herpesvirus 1 (family:
Herpesviridae, subfamily: Alphaherpesvirinae, genus: Sim-
plexvirus). This designation is based on virologic characteris-
tics and serologic cross-reactivity with other members of the
genus Simplexvirus, namely HSV type 1 (HSV-1), the caus-
ative agent of oral herpetic ulcers (cold sores) in humans and
HSV type 2 (HSV-2), the agent of human genital herpes (3).
Structure and Life Cycle
B virus is a large, double-stranded DNA virus with numer-
ous open reading frames, some of which share approximately
79% amino acid sequence identity with HSV-1 and HSV-2 (4).
The viral genome is G+C rich (75% G+C), the highest of any
known herpesvirus (4). The B-virus genome is only partially
sequenced, but thus far, is colinear with that of HSV (5). Elec-
tron micrograph studies of B virus show a typical herpesvirus
structure (6), including an electron dense core with viral DNA
inside an icosapentahedral capsid surrounded by an amor-
phous tegument protein layer and a lipid envelope studded
with viral glycoproteins. Glycoproteins on the viral envelope
mediate attachment to and entry into the host cell. For HSV, 11
glycoproteins are known (gB–gM), and another is predicted
(gN). Of these, nine have been identified in B virus (5).
In general, alphaherpesviruses infect mucosal epithelia fol-
lowed by one or more rounds of replication in epithelial cells.
B virus likely replicates with three consecutive rounds of tran-
scription (the α, β, and γ genes), as has been established for
HSV. The infected cells are lysed, releasing virus to spread to
other cells and sensory nerve endings, although direct entry
into neurons without replication can occur (3). Virus can also
spread from cell to cell without contacting the extracellular
environment. Spread of the virus to and from the nerve ganglia
occurs by axonal transport, which has been demonstrated for B
virus in experimentally infected mice (7). The virus estab-
lishes latency in the nerve ganglia. Latency is characterized by
a lack of viral replication and limited viral transcription. Peri-
odic reactivation from latency delivers the virus to mucosal
epithelial cells, where it replicates; infectious virus is released*University of California, Davis, California, USA
O
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from the mucosal epithelium. A heavy viral load in the ganglia
may increase the frequency of reactivation and shedding (8).
Recent findings from the study of primary and recurrent HSV-
2 infection indicate that most episodes of recurrent viral shed-
ding are asymptomatic. B-virus shedding in macaques also
appears to be primarily asymptomatic (9–11).
B-Virus Infection in Macaques
B-virus infection has been reported most commonly in the
rhesus and cynomolgus macaque (M. facicularis), two species
used extensively in biomedical research. B virus has also been
isolated from the stumptail (M. artoides), pig-tailed (M. nem-
estrina), Japanese (M. fuscata), bonnet (M. radiata), and Tai-
wan (M. cyclopis) macaque (12). Sequence comparisons and
restriction fragment length polymorphism analysis of viral
genomes have demonstrated strain differences between B-
virus isolates from different macaque species (13). Research
suggests that B virus from rhesus macaques may be more
pathogenic for humans than B virus from other macaque spe-
cies (13).  Where the species of macaque is noted, cases of
human B-virus infection have all been associated with direct
or indirect exposure specifically to rhesus macaques (14–19).
The ability of nonrhesus strains of B virus to infect humans is
not well understood. 
Little is known about the biology of B virus in its natural
host. Infection is usually acquired at sexual maturity (2–4
years of age for rhesus macaques). As seen in humans with
HSV, B-virus seropositivity increases with population age;
seropositivity rates of 80% to 100% occur among most adult
captive macaque populations (10,20,21). Oral herpetic lesions
such as gingivostomatitis, oral and lingual ulcers, and conjunc-
tivitis have been described, but are usually associated with
immunosuppression or stress attributable to recent importation
or crowded housing conditions (12,22,23). Genital lesions
have not been observed in macaques, although genital infec-
tion has been demonstrated by polymerase chain reaction
(PCR) (9), virus isolation from the genital mucosa (10,11), and
culture of the sacral ganglia (11). In general, macaques remain
asymptomatic, and identification of oral herpetic lesions is
sufficient grounds for euthanasia of the affected animal. The
infrequent cases of disseminated B-virus disease in macaques
are most often associated with immunosuppression, caused by
either chemotherapy or concurrent infection as with simian
type D virus (22). Although severe HSV disease is commonly
observed in humans co-infected with HIV, no cases of B-virus
disease associated with simian immunodeficiency virus infec-
tion in macaques have been reported (24).
Relatively few studies have surveyed macaques for B-
virus shedding, and detection of B virus by culture is rare.
Most cases of B-virus detection in asymptomatic macaques by
culture or PCR are associated with breeding season stress
(9,10), immunosuppression (25), or primary infection (10,11).
The true frequency of B-virus shedding in macaque popula-
tions is not known but is likely to be low. 
Most cases of human B-virus infection have been associ-
ated with apparently healthy macaques (i.e., no obvious her-
petic lesions), which indicates asymptomatic shedding of the
virus. Lack of clinical signs of recurrent infection makes iden-
tification of shedding animals difficult. People working with
these animals should consider every animal a potential source
of B virus and use proper protective equipment and care when
handling them (21,26–28). 
Human B Virus Infection
Most cases of human B-virus infection have involved
direct contact with macaques, such as a bite, scratch, or
mucosal contact with body fluid or tissue (12,14–16,19,27,28).
Indirect contact, such as injury from a contaminated fomite
(e.g., needle puncture or cage scratch), has also resulted in
human infection. Human-to-human transmission has been doc-
umented in one case (15); however, further investigation has
indicated that the risk for secondary transmission is low (18).
Human B-virus disease generally occurs within 1 month of
exposure (21), commonly with an incubation period of a few
days to a week. The development and progression of disease
depend on the site of exposure and the amount of virus inocu-
lated. Vesicular lesions have not been consistently found at the
site of exposure (12,14–19). Disease often starts with general
influenzalike symptoms of fever, muscle aches, fatigue, and
headache (12,14). Other variable symptoms include lymphad-
enitis and lymphangitis, nausea and vomiting, abdominal pain,
and hiccups (12,14). Neurologic signs develop when the virus
spreads to the central nervous system and vary with the part of
the brain or spinal cord affected. Hyperesthesias, ataxia, diplo-
pia, agitation, and ascending flaccid paralysis have been
described after virus spread to the brain (12,14–19).  Virus
spread to the central nervous system is an ominous sign; even
with antiviral therapy and supportive care, most patients die,
and those who survive often have serious neurologic sequelae.
Deaths are often attributed to respiratory failure associated
with ascending paralysis. 
The possibility of asymptomatic or mild B-virus infection
in humans has been suggested (2,29). A carefully controlled
study of B-virus antibodies in persons with macaque contact
and controls without contact showed no evidence of asymp-
tomatic human infection or a carrier state for B virus (29).
Although HSV antibodies can neutralize the virus in vitro, anti-
body titers to HSV are not protective in human cases of B-virus
exposure or infection (21,29) and can confound diagnostic test-
ing because of cross-reactivity. Asymptomatic human infection
with B virus appears exceedingly rare if it occurs at all.
With the discovery of simian immunodeficiency virus and
its identification as a model for HIV infection, the number of
macaques used in research has increased, as has the number of
human B-virus cases. Guidelines for reducing and controlling
exposure were first published in 1987 (26) by a group of veter-
inarians, physicians, and research scientists called the B Virus
Working Group. Guidelines were again published in 1995 (21)
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by a new B Virus Working Group to include new information
and provide protocols for handling exposures. Further recom-
mendations were made in 1998 to emphasize the need for lim-
iting mucosal exposure to potential sources of B virus (19,28).
New guidelines by another B Virus Working Group have
recently been published (30).
Treatment of B-Virus Infection in Humans
The 2002 B Virus Working Group guidelines address
issues to be considered in cases of possible exposure to or
infection with the virus (30) and reflect consensus of opinion
at the time the guidelines were written. In cases of exposure,
an established and frequently updated protocol should be used
based on these guidelines and on current literature regarding
human cases of B-virus infection. Additional information and
contacts are available from: URL: http://www.cdc.gov/niosh/
hid5.html, http://www.haz-map.com/Macaque.htm.
According to the guidelines, the most important action in a
case of potential exposure to B virus is to rapidly and thor-
oughly cleanse the wound or exposure site. HSV can enter
sensory nerve endings within 5 minutes of exposure, and B
virus is likely to infect just as rapidly. Bite wounds, scratches,
or puncture wounds of nonmucosal surfaces should be
cleansed with soap or detergent for at least 15 min (30). The
time spent mechanically cleansing the area is more important
than the type of cleansing solution used. Mucosal surfaces
should be rinsed with sterile saline or running water for 15
min. Immediate cleansing or rinsing can inactivate and wash
away virus present in the exposure site. After immediately
cleansing the wound or exposure area, the person should seek
medical attention, specifically from a physician identified in
the facility’s protocol as someone familiar with treating these
B-virus exposure cases. 
A physician with a patient who has potentially been
exposed to B virus faces a conundrum. Before onset of neuro-
logic symptoms, antiviral therapy is successful. However, few
cases of potential exposure lead to infection. Prophylactic treat-
ment is unnecessary in most cases of potential exposure
because treatment can confound diagnostic testing by interfer-
ing with the humoral immune response (21). However, the
2002 B Virus Working Group viewed prophylactic treatment
more favorably in light of the efficacy of postexposure prophy-
laxis for nosocomial HIV exposure and the availability of new
antiherpes drugs, such as valacyclovir, that achieve higher
serum levels with a more reasonable dosing schedule (30).
Although severity of injury may prompt use of antiviral ther-
apy, the amount of inoculated virus determines if infection is
likely to occur. In some cases, minor scratches or needle-sticks
have transmitted B virus, while bites with severe tissue lacera-
tion have healed without infection. The primary factor to con-
sider is whether cleansing (or rinsing, if it is a mucosal surface)
was initiated immediately and performed for the recommended
15 min (21). Inadequate cleansing of the wound or exposed
area in a timely manner could warrant prophylactic antiviral
therapy. Other indications for immediate initiation of antiviral
treatment include the identification of herpetic lesions in the
source animal, injuries involving the head or neck, and mucosal
exposure to macaque fluid. Because of the prevalence of
asymptomatic B-virus shedding in macaques, the clinical
appearance of the monkey involved (if the animal is identified)
may not be helpful in evaluating the possibility of transmission.
In addition to working closely with a physician trained to
handle cases of B-virus exposure and infection, taking samples
from the exposed person and the source animal is important
for virus culture and serologic testing. A list of recommended
swabs for virus culture and serum samples is available from:
URL: http://www.gsu.edu/~wwwvir/index.html. 
Detection of B Virus
Early suspicion and rapid diagnosis of B-virus infection
are critical to the control of human infection. The extreme
cross-reactivity of primate alphaherpesviruses has required the
development of diagnostic methods that can differentiate
between HSV and B-virus infection. Despite the inherent risk
for exposure, direct culture of B virus has been the standard
for diagnosis of infection. Culture of B virus requires a special
containment facility since the virus is a biosafety level 4
pathogen (31). Serologic methods for the detection of B-virus
infection have also involved propagation of the virus in tissue
culture to produce antigen. However, the substitution of
related antigens appears to work well for serologic tests. The
most promising of these antigens is herpesvirus papio 2, an
alphaherpesvirus of baboons that is as closely related to B
virus as HSV-1 and HSV-2 are to each other (32,33). Serologic
methods are useful only for retrospective analysis, not for ther-
apeutic decisions, which need to be made rapidly in cases of
potential human infection. 
More recently, PCR methods have allowed direct demon-
stration of B-virus infection without the risk of working with
virus cultures (9,34,35). PCR methods have been hampered by
the close genetic relationship between primate alphaherpesvi-
ruses; many require post-PCR techniques to definitively dif-
ferentiate between HSV and B virus.  To specifically detect B
virus, we developed a method using quantitative real-time
PCR, whose potential application for human clinical samples
in cases of exposure warrants further study (9). Samples to be
tested by PCR may contain B virus and must be handled
accordingly (31).
B Virus Outside the Research Setting
The cases of human B-virus infection that have been
described have all occurred in relation to contact with
macaques in a biomedical research setting. However, this set-
ting is not the only one in which humans have contact with
macaques. The Woburn Safari Park in the U.K. recently culled
all B-virus–positive macaques from its facility (36). No cases
of human infection have been documented despite contact
between macaques and humans driving through the park, but
the risk perceived by this situation warranted the action. B
virus is also prevalent in free-ranging macaques native to
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Southeast Asia (12,37). A recent survey of workers at a
Balinese Hindu temple that is a refuge for free-ranging
macaques and a tourist attraction showed that contact between
humans and macaques sufficient to transmit B virus com-
monly occurred. A serosurvey of 38 macaques in the area
showed that 31 (81.6%) were B-virus seropositive. No cases
consistent with B-virus disease in humans have been described
in this area of Bali or in other areas of Southeast Asia where
humans are in contact with free-ranging macaques. However,
in cases of encephalitis, B virus may not be considered.
In other situations, particularly when potentially seroposi-
tive macaques have been domesticated as pets, opportunities
for exposure to B virus are frequent. One report documented
many instances of potential exposures from bites, scratches,
food sharing, close physical contact, and even shared chewing
gum (38). This study also found that children were three times
more likely than adults to be bitten by pet macaques. Although
the number of macaques kept as pets is probably small, the
risk of B-virus infection is increased because of the lack of
precautions and the extent of contact between monkey and
owner. The risk of B-virus infection is low, but the risk for
death is high. 
Specific Pathogen-Free Colony Development
In 1989, the National Institutes of Health’s National Center
for Research Resources started funding specific pathogen-free
macaque colony development. The timing and local nature of
B-virus reactivation and shedding make detecting infection in
an animal difficult. Therefore, serologic methods are used to
screen and monitor animals for consideration as pathogen-free.
Numerous negative serologic results are necessary to deter-
mine a macaque’s B-virus status. Although specific pathogen-
free status reduces the likelihood of infection, this status does
not eliminate the risk for infection entirely. Full protective
equipment should be used for working with all macaques
regardless of their pathogen status. While population numbers
in these specific pathogen-free colonies are increasing, the
demand for pathogen-free animals will continue to exceed the
supply for some time (24). 
B-Virus Vaccine Development 
While antiviral therapy has substantially improved the sur-
vival rate for human B-virus infection, fatal cases still occur
(19,28). The ability of the virus to modulate and evade the
immune response has stymied vaccine development for most
herpesvirus infections. A vaccine for use in rhesus macaques
could reduce transmission of the virus and, over time, reduce
the prevalence of infection in captive macaque populations.
Given the lack of an effective vaccine for HSV after years of
research effort and clinical trials, development of a B-virus
vaccine presents a challenge.
A formalin-inactivated B-virus vaccine was developed and
tested in the 1960s (39). Although this vaccine did induce an
antibody response, antibody titers were low, and frequent
boosters (every 3 months) were required (39). Recently, suc-
cessful use of a vaccinia vector to deliver the gD gene of B
virus was demonstrated in rabbits with protection of 10 (91%)
of 11 animals from B-virus challenge (40). A DNA vaccine
against B virus has also recently been described (41). Glyco-
protein B of B virus delivered in a plasmid vector induced a
humoral response in both mice and rhesus macaques.
Although no challenge experiments were performed in mon-
keys, an anamnestic-like response upon boosting was noted.
While the ability of a B-virus antibody response to protect
from infection is not known, studies of HSV suggest that an
antibody response alone is not protective. Both the vaccinia
and DNA vaccine approaches described above are likely to
induce cellular immunity to B virus, although the cellular
response was not studied by either group (40,41). As clinical
trials of candidate HSV vaccines progress, the development of
a B-virus vaccine for use in macaques or humans at risk for
exposure should be considered.
Conclusion
The potential for fatal human infection with B virus is a
constant concern because frequent exposures occur to humans
in the course of caring for and using macaques in a research
setting. Personal protective equipment and safe handling pro-
cedures have limited the incidence of human disease. How-
ever, little is known about the biology of B virus in the natural
macaque host. A clear understanding of the real risk for B-
virus shedding in its natural host will help identify opportuni-
ties to prevent or limit zoonotic B-virus disease.
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